Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00116649 · ClinicalTrials.gov registry record · Phase 4
Open-Label Safety Study to Evaluate Imiquimod Cream, 5% for Large Areas of Actinic Keratosis
A Phase 4 study, sponsored by Graceway Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 551
- Enrollment target
NCT00116649 is a Phase 4 study that has completed, run by Graceway Pharmaceuticals. The registered enrollment target is 551 participants.
The verdict
NCT00116649, a Phase 4 study, has completed, sponsored by Graceway Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 551 participants
- Enrollment target
Study Summary
Actinic keratosis (AK) is a skin condition that shows up on skin routinely exposed to the sun, such as the face, scalp, shoulders, chest, back, arms, and hands. The purpose of this study is to evaluate the safety of one, two, or three cycles of imiquimod for the treatment of AK. The AK lesions treated can be in adjacent and nonadjacent areas of the head, torso, and extremities. The total surface area for the AK lesions must be greater than 25 cm2. The secondary objective is to evaluate the effectiveness of treatment with imiquimod in people with large surface areas of AK.
Interventions
- DRUG imiquimod cream
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 551 participants |
| Start Date | 2005-06 |
| Est. Completion | 2007-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00116649
The ClinicalTrials.gov registry entry for NCT00116649 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 551 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Graceway Pharmaceuticals, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which imiquimod cream is the first listed.
NCT00116649 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00116649 about?
NCT00116649 is a clinical study titled "Open-Label Safety Study to Evaluate Imiquimod Cream, 5% for Large Areas of Actinic Keratosis". Actinic keratosis (AK) is a skin condition that shows up on skin routinely exposed to the sun, such as the face, scalp, shoulders, chest, back, arms, and hands. The purpose of this study is to evaluate the safety of one, two, or three cycles of imiquimod for the treatment of AK. The AK lesions treat...
What is the current status of trial NCT00116649?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 551 participants. The study started on 2005-06. Estimated completion is 2007-05.
What interventions are being tested in trial NCT00116649?
The interventions under investigation include: imiquimod cream (DRUG).
Who is sponsoring clinical trial NCT00116649?
This trial is sponsored by Graceway Pharmaceuticals, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.